Key result
Low dose aspirin (81 mg/day) significantly suppressed collagen-induced platelet aggregation (41.7% vs 71.8%; P<0.005) but did not reduce elevated PAI-1 activity in permanent pacemaker patients.
Why the study?
Does low dose aspirin reduce augmented PAI-1 activity in patients with permanent pacemakers?
Observational (n=36)
Does low dose aspirin reduce augmented PAI-1 activity in patients with permanent pacemakers?
Absolute Event Rate: 41.7% vs 71.8%
p-value: p=<0.005
Low dose aspirin does not suppress the elevated PAI-1 activity observed in patients with permanent pacemakers, despite effectively reducing platelet aggregation.
Low-dose aspirin does not lower PAI-1 in pacemaker patients despite suppressing aggregation; leaves open targeted fibrinolysis strategies.
To clarify the activity states of coagulation and fibrinolysis in patients with a permanent pacemaker, we studied 29 patients more than 4 months after operation. They were divided into a single pacemaker lead group (S, n = 14) and a double lead group (D, n = 15). Prothrombin time, activated partial thromboplastin time, fibrinogen, antithrombin III, tissue-type plasminogen activator (tPA) activity, plasminogen activator inhibitor type-1 (PAI-1) activity, and platelet aggregation were measured and compared to those in an age-matched control group (C, n = 7). The effects of low dose aspirin (81 mg/day) in the patients (n = 21) were also studied 2 weeks after administration. PAI-1 activity in groups S and D was significantly higher than that in the group C (53.5 +/- 36.5, 86.8 +/- 59.2 ng/mL vs 19.4 +/- 7.2 ng/mL; P < 0.01 and P < 0.005). Platelet aggregation induced by collagen was slightly higher in groups S and D than group C. Other parameters were not significantly different. In the patients, low dose aspirin significantly suppressed collagen induced platelet aggregation (71.8 +/- 20.3% vs 41.7 +/- 28.3%; P < 0.005), but not PAI-1 activity. tPA activity was increased significantly by the low dose aspirin administration (3.94 +/- 1.85 ng/mL vs 2.48 +/- 1.19 ng/mL; P < 0.005). Thus, PAI-1 activity in patients with a permanent pacemaker is elevated, and the activity is not suppressed by low dose aspirin unlike the platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Abe et al. (1994) conducted an observational in Permanent pacemakers (n=36). Low dose aspirin vs. Baseline (before administration) was evaluated on Collagen induced platelet aggregation (p=<0.005). Low dose aspirin (81 mg/day) significantly suppressed collagen-induced platelet aggregation (41.7% vs 71.8%; P<0.005) but did not reduce elevated PAI-1 activity in permanent pacemaker patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: